TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02293629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BMS-986147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BMS-986147
Study: NCT00297154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification (diet, exercise, and behavior)
Description: Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
Study: NCT06580808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fontan Training Group
Description: The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
Study: NCT01977755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04632186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXOPULSE Mollii suit
Description: All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment).
Study: NCT00223041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Description: Arm A receives fluvastatin Arm b receives no fluvastatin
Study: NCT01842139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 126-134 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 126-134 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 126-134 peptide vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04452708

Intervention type: DEVICE
Intervention: HFNC
Description: HFNV vs NIV vs conventional nasal cannula
Study: NCT04701398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: Exercise + nutritional supplementation + psychological advice
Study: NCT01792011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Description: In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
Study: NCT03214913

Intervention type: OTHER
Group type: OTHER
Intervention: Early Goal Directed Therapy
Description: EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: Ruijin Strategy
Description: Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%.
Study: NCT02745431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01861223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)
Study: NCT05496270

Intervention type: PROCEDURE
Intervention: total mesorectal excision

Intervention type: PROCEDURE
Intervention: total mesorectal excision
Study: NCT03313557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wee-1 kinase inhibitor AZD1775
Description: Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
Study: NCT01843699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate flexible dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tablets
Study: NCT03204994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Fluorescence guided lymphatic mapping using indocyanine green.
Study: NCT00655408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron
Description: Iron supplementation.
Study: NCT04858646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental( Group A ): Aerobic exercises
Description: Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional( Group B): Conventional Physical therapy
Description: The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
Study: NCT02208193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and psycho-behavioral effects of an artistic dimension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and psycho-behavioral effects of an artistic dimension
Study: NCT01491854

Intervention type: OTHER
Group type: OTHER
Intervention: Bloodsampling
Description: Bloodsampling
Study: NCT03404128

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
Study: NCT02571504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plasticity-based Adaptive Cognitive Remediation (PACR)
Description: Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plasticity-based Adaptive Cognitive Remediation (PACR)
Description: Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
Study: NCT02347761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg BID eFlow (CS) nebulizer
Description: SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 25 mcg BID eFlow (CS) nebulizer
Description: SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID eFlow Closed System (CS) nebulizer
Description: Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
Study: NCT02052505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication review
Description: The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
Study: NCT05372835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: La Chlogen mouthwash
Description: Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
Study: NCT00781300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.5%
Description: Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1%
Description: The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
Study: NCT04301336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: 50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study: NCT05372835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: La Chlogen mouthwash and La Chlogen periodontal flosser
Description: Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
Study: NCT01496001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy, axillary block dissection, breast conserving surgery
Description: Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Adjuvant radiotherapy carried out by institutional protocols.
Study: NCT01694160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Zemplar (paricalcitol) 2ug daily, oral intake
Study: NCT04141241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecklonia cava Phlorotannin
Description: Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecklonia cava Phlorotannin
Description: Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecklonia cava Phlorotannin
Description: Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
Study: NCT00982332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic sodium chloride solution (placebo)
Description: 4 ml intramuscular
Study: NCT01843699

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 4-session gambling cognitive restructuring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-session gambling cognitive restructuring
Study: NCT00982332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic sodium chloride solution (placebo)
Description: 4 ml intramuscular
Study: NCT01117922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Group
Study: NCT04301336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: 50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: 50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study: NCT01346059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
Study: NCT03321500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Versacryl soft liner
Description: Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silicone-based soft liner
Description: gold standard for denture relining material
Study: NCT01611935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressin
Description: After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
Study: NCT04122742

Intervention type: PROCEDURE
Intervention: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.
Description: Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.

Intervention type: OTHER
Intervention: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy
Description: induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons

Intervention type: OTHER
Intervention: Histone acetylation profiles of cells of SRT patients with CREBBP mutations
Description: Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing

Intervention type: OTHER
Intervention: Functional involvement of identified epigenetic alterations
Description: Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.

Intervention type: BIOLOGICAL
Intervention: Culture of lymphoblastoid line from blood sample
Description: Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
Study: NCT03437863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
Study: NCT01538277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact Force during ablation
Description: Radio Frequency Ablation procedure with real-time contact force information known to the operator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ablation procedure
Description: Standard ablation procedure
Study: NCT02909712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP)
Description: Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHA-PQP)
Description: Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
Study: NCT01733940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of a dressing with clorhexidine gluconate in intravascular catheters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of a dressing without clorhexidine gluconate
Study: NCT02810041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yoghurts enriched with XXS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: yoghurts non enriched with XXS